Current approaches to management of bone sarcoma in adolescent and young adult patients.
Ewing sarcoma
adolescent and young adult (AYA)
bone sarcoma
clinical trials
local control
osteosarcoma
radiation
surgery
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
revised:
02
10
2021
received:
21
06
2021
accepted:
16
10
2021
pubmed:
13
11
2021
medline:
28
4
2022
entrez:
12
11
2021
Statut:
ppublish
Résumé
Bone tumors are a group of histologically diverse diseases that occur across all ages. Two of the commonest, osteosarcoma (OS) and Ewing sarcoma (ES), are regarded as characteristic adolescent and young adult (AYA) cancers with an incidence peak in AYAs. They are curable for some but associated with unacceptably high rates of treatment failure and morbidity. The introduction of effective new therapeutics for bone sarcomas is slow, and to date, complex biology has been insufficiently characterized to allow more rapid therapeutic exploitation. This review focuses on current standards of care, recent advances that have or may soon change that standard of care and challenges to the expert clinical research community that we suggest must be met.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e29442Subventions
Organisme : Department of Health
Pays : United Kingdom
Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7-30.
Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence- SEER Research Limited-Field DATA, 21 Registries, Nov 2020 Sub (2000-2018)-Linked to County Attributes-Time Dependent (1990-2018)-Income/Rurality, 1969-2019 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2021, based on the November 2020 submission.
Amadeo B, Penel N, Coindre JM, et al. Incidence and time trends of sarcoma (2000-2013): results from the French network of cancer registries (FRANCIM). BMC Cancer. 2020;20:190.
Gatta G, Capocaccia R, Botta L, et al. Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet-a population-based study. Lancet Oncol. 2017;18:1022-1039.
Whelan J, McTiernan A, Cooper N, et al. Incidence and survival of malignant bone sarcomas in England 1979-2007. Int J Cancer. 2012;131:E508-517.
de Pinieux G, Karanian M, Le Loarer F, et al. Nationwide incidence of sarcomas and connective tissue tumors of intermediate malignancy over four years using an expert pathology review network. PLoS One. 2021;16:e0246958.
Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer. 2009;115:1531-1543.
Hameed M, Mandelker D. Tumor syndromes predisposing to osteosarcoma. Adv Anat Pathol. 2018;25:217-222.
Mirabello L, Zhu B, Koster R, et al. Frequency of pathogenic germline variants in cancer-susceptibility genes in patients with osteosarcoma. JAMA Oncol. 2020;6:724-734.
Jawad MU, Cheung MC, Min ES, et al. Ewing sarcoma demonstrates racial disparities in incidence-related and sex-related differences in outcome: an analysis of 1631 cases from the SEER database, 1973-2005. Cancer. 2009;115:3526-3536.
Turc-Carel C, Aurias A, Mugneret F, et al. Chromosomes in Ewing's sarcoma. I. An evaluation of 85 cases of remarkable consistency of t(11;22)(q24;q12). Cancer Genet Cytogenet. 1988;32:229-238.
Sorensen PH, Lessnick SL, Lopez-Terrada D, et al. A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor. ERG Nat Genet. 1994;6:146-151.
Tirode F, Surdez D, Ma X, et al. Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations. Cancer Discov. 2014;4:1342-1353.
Brohl AS, Patidar R, Turner CE, et al. Frequent inactivating germline mutations in DNA repair genes in patients with Ewing sarcoma. Genet Med. 2017;19:955-958.
Abbott D, O'Brien S, Farnham JM, et al. Increased risk for other cancers in individuals with Ewing sarcoma and their relatives. Cancer Med. 2019;8:7924-7930.
Grunewald TGP, Cidre-Aranaz F, Surdez D, et al. Ewing sarcoma. Nat Rev Dis Primers. 2018;4:5.
Miettinen M, Felisiak-Golabek A, Luina Contreras A, et al. New fusion sarcomas: histopathology and clinical significance of selected entities. Hum Pathol. 2019;86:57-65.
Antonescu CR, Owosho AA, Zhang L, et al. Sarcomas With cic-rearrangements are a distinct pathologic entity with aggressive outcome: a clinicopathologic and molecular study of 115 cases. Am J Surg Pathol. 2017;41:941-949.
Cohen-Gogo S, Cellier C, Coindre JM, et al. Ewing-like sarcomas with BCOR-CCNB3 fusion transcript: a clinical, radiological and pathological retrospective study from the Societe Francaise des Cancers de L'Enfant. Pediatr Blood Cancer. 2014;61:2191-2198.
Dahlin DC, Coventry MB. Osteogenic sarcoma. A study of six hundred cases. J Bone Joint Surg Am. 1967;49:101-110.
Link MP, Goorin AM, Miser AW, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med. 1986;314:1600-1606.
Souhami RL, Craft AW, Van der Eijken JW, et al. Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European osteosarcoma intergroup. Lancet. 1997;350:911-917.
Bramwell VH, Burgers M, Sneath R, et al. A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup. J Clin Oncol. 1992;10:1579-1591.
Lewis IJ, Nooij MA, Whelan J, et al. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst. 2007;99:112-128.
Marina NM, Smeland S, Bielack SS, et al. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. Lancet Oncol. 2016;17:1396-1408.
Smeland S, Bielack SS, Whelan J, et al. Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. Eur J Cancer. 2019;109:36-50.
Jeys LM, Grimer RJ, Carter SR, et al. Post operative infection and increased survival in osteosarcoma patients: are they associated? Ann Surg Oncol. 2007;14:2887-2895.
Kim MS, Lee SY, Lee TR, et al. Prognostic nomogram for predicting the 5-year probability of developing metastasis after neo-adjuvant chemotherapy and definitive surgery for AJCC stage II extremity osteosarcoma. Ann Oncol. 2009;20:955-960.
Song WS, Jeon DG, Kong CB, et al. Tumor volume increase during preoperative chemotherapy as a novel predictor of local recurrence in extremity osteosarcoma. Ann Surg Oncol. 2011;18:1710-1716.
Moore C, Eslin D, Levy A, et al. Prognostic significance of early lymphocyte recovery in pediatric osteosarcoma. Pediatr Blood Cancer. 2010;55:1096-1102.
Bielack SS, Smeland S, Whelan JS, et al. Methotrexate, doxorubicin, and cisplatin (map) plus maintenance pegylated interferon alfa-2b versus map alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative map: first results of the euramos-1 good response randomized controlled trial. J Clin Oncol. 2015;33:2279-2287.
Duffaud F, Digue L, Mercier C, et al. Recurrences following primary osteosarcoma in adolescents and adults previously treated with chemotherapy. Eur J Cancer. 2003;39:2050-2057.
Kempf-Bielack B, Bielack SS, Jurgens H, et al. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the cooperative osteosarcoma study group (COSS). J Clin Oncol. 2005;23:559-568.
Bielack SS, Kempf-Bielack B, Branscheid D, et al. Second and subsequent recurrences of osteosarcoma: presentation, treatment, and outcomes of 249 consecutive cooperative osteosarcoma study group patients. J Clin Oncol. 2009;27:557-565.
Palmerini E, Torricelli E, Cascinu S, et al. Is there a role for chemotherapy after local relapse in high-grade osteosarcoma? Pediatr Blood Cancer. 2019;66:e27792.
Bacci G, Briccoli A, Longhi A, et al. Treatment and outcome of recurrent osteosarcoma: experience at Rizzoli in 235 patients initially treated with neoadjuvant chemotherapy. Acta Oncol. 2005;44:748-755.
Briccoli A, Rocca M, Salone M, et al. Resection of recurrent pulmonary metastases in patients with osteosarcoma. Cancer. 2005;104:1721-1725.
Matsubara E, Mori T, Koga T, et al. Metastasectomy of pulmonary metastases from osteosarcoma: prognostic factors and indication for repeat metastasectomy. Respir Med. 2015:570314.
Treasure T, Fiorentino F, Scarci M, et al. Pulmonary metastasectomy for sarcoma: a systematic review of reported outcomes in the context of Thames Cancer Registry data. BMJ Open. 2012;2:e001736.
Treasure T, Milosevic M, Fiorentino F, et al. Pulmonary metastasectomy: what is the practice and where is the evidence for effectiveness? Thorax. 2014;69:946-949.
Ferrari S, Briccoli A, Mercuri M, et al. Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival. J Clin Oncol. 2003;21:710-715.
Palmerini E, Setola E, Grignani G, et al. High dose ifosfamide in relapsed and unresectable high-grade osteosarcoma patients: a retrospective series. Cells. 2020;9:2389.
Casali PG, Bielack S, Abecassis N, et al. Bone sarcomas: ESMO-PaedCan-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv79-iv95.
Burgert EO Jr, Nesbit ME, Garnsey LA, et al. Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: intergroup study IESS-II. J Clin Oncol. 1990;8:1514-1524.
Nesbit ME Jr, Gehan EA. Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long-term follow-up of the first intergroup study. J Clin Oncol. 1990;8:1664-1674.
Miser JS, Kinsella TJ, Triche TJ, et al. Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol. 1987;5:1191-1198.
Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med. 2003;348:694-701.
Paulussen M, Craft AW, Lewis I, et al. Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment-cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. J Clin Oncol. 2008;26:4385-4393.
Le Deley MC, Paulussen M, Lewis I, et al. Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: results of the randomized noninferiority Euro-EwinG99-R1 trial. J Clin Oncol. 2014;32:2440-2448.
Womer RB, Daller RT, Fenton JG, et al. Granulocyte colony stimulating factor permits dose intensification by interval compression in the treatment of Ewing's sarcomas and soft tissue sarcomas in children. Eur J Cancer. 2000;36:87-94.
Womer RB, West DC, Krailo MD, et al. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol. 2012;30:4148-4154.
Anderton J, Moroz V, Marec-Berard P, et al. International randomised controlled trial for the treatment of newly diagnosed EWING sarcoma family of tumours-EURO EWING 2012. Protocol Trials. 2020;21:96.
Brennan B, Kirton L, Marec-Berard P, et al. Comparison of two chemotherapy regimens in Ewing sarcoma (ES): overall and subgroup results of the Euro Ewing 2012 randmoized trial (EE2012). J Clin Oncol. 2020;38:11500-11500.
Schwartz CL, Wexler LH, Krailo MD, et al. Intensified chemotherapy with dexrazoxane cardioprotection in newly diagnosed nonmetastatic osteosarcoma: a report from the children's oncology group. Pediatr Blood Cancer. 2016;63:54-61.
Mascarenhas L, Felgenhauer JL, Bond MC, et al. Pilot study of adding vincristine, topotecan, and cyclophosphamide to interval-compressed chemotherapy in newly diagnosed patients with localized Ewing sarcoma: a report from the children's oncology group. Pediatr Blood Cancer. 2016;63:493-498.
Meyers PA, Ambati SR, Slotkin EK, Dela Cruz F, Wexier LH. The addition of cycles of irinotecan/temozolomide (i/T) to cycles of vincristine, doxorubicin, cyclophosphamide (VDC) and cycles of ifosfamide, etoposide (IE) for the treatment of Ewing sarcoma (ES). Presented at the 2018 Am Soc Clin Oncol. May 20, 2018.
Barker LM, Pendergrass TW, Sanders JE, et al. Survival after recurrence of Ewing's sarcoma family of tumors. J Clin Oncol. 2005;23:4354-4362.
Cotterill SJ, Ahrens S, Paulussen M, et al. Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol. 2000;18:3108-3114.
Stahl M, Ranft A, Paulussen M, et al. Risk of recurrence and survival after relapse in patients with Ewing sarcoma. Pediatr Blood Cancer. 2011;57:549-553.
McCabe M, Kirton L, Khan M, et al. Results of the second interim assessment of rEECur, an international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES). J Clin Oncol. 2020;38:11502-11502.
McCabe M, Moroz V, Khan M, et al. Results of the first interim assessment of rEECur, an international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma. Am Soc Clin Oncol. 2019;37:11007-11007.
Ahmed SK, Randall RL, DuBois SG, et al. Identification of patients with localized Ewing sarcoma at higher risk for local failure: a report from the children's oncology group. Int J Radiat Oncol Biol Phys. 2017;99:1286-1294.
Andreou D, Ranft A, Gosheger G, et al. Which factors are associated with local control and survival of patients with localized pelvic Ewing's sarcoma? A retrospective analysis of data from the Euro-Ewing99 trial. Clin Orthop Relat Res. 2020;478:290-302.
Schuck A, Ahrens S, Paulussen M, et al. Local therapy in localized Ewing tumors: results of 1058 patients treated in the CESS 81, CESS 86, and EICESS 92 trials. Int J Radiat Oncol Biol Phys. 2003;55:168-177.
Foulon S, Brennan B, Gaspar N, et al. Can postoperative radiotherapy be omitted in localised standard-risk Ewing sarcoma? An observational study of the Euro-E.W.I.N.G group. Eur J Cancer. 2016;61:128-136.
Casey DL, Meyers PA, Alektiar KM, et al. Ewing sarcoma in adults treated with modern radiotherapy techniques. Radiother Oncol. 2014;113:248-253.
Gerrand C, Athanasou N, Brennan B, et al. UK guidelines for the management of bone sarcomas. Clin Sarcoma Res. 2016;6.
Balamuth NJ, Womer RB. Ewing's sarcoma. Lancet Oncol. 2010;11:184-192.
Bernstein M, Kovar H, Paulussen M, et al. Ewing's sarcoma family of tumors: current management. Oncologist. 2006;11:503-519.
DuBois SG, Krailo MD, Gebhardt MC, et al. Comparative evaluation of local control strategies in localized Ewing sarcoma of bone: a report from the Children's. Oncol Group Cancer. 2015;121:467-475.
Indelicato DJ, Keole SR, Shahlaee AH, et al. Definitive radiotherapy for Ewing tumors of extremities and pelvis: long-term disease control, limb function, and treatment toxicity. Int J Radiat Oncol Biol Phys. 2008;72:871-877.
Donaldson SS. Ewing sarcoma: radiation dose and target volume. Pediatr Blood Cancer. 2004;42:471-476.
Ronchi L, Buwenge M, Cortesi A, et al. Whole lung irradiation in patients with osteosarcoma and Ewing sarcoma. Anticancer Res. 2018;38:4977-4985.
Meyers PA, Schwartz CL, Krailo MD, et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival-a report from the Children's Oncology Group. J Clin Oncol. 2008;26:633-638.
Meyers PA, Schwartz CL, Krailo M, et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 2005;23:2004-2011.
Meyers PA. Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma. Expert Rev Anticancer Ther. 2009;9:1035-1049.
DeLaney TF, Park L, Goldberg SI, et al. Radiotherapy for local control of osteosarcoma. Int J Radiat Oncol Biol Phys. 2005;61:492-498.
Stacchiotti S, Sommer J; Chordoma Global Consensus Group. Building a global consensus approach to chordoma: a position paper from the medical and patient community. Lancet Oncol. 2015;16:e71-83.
Riedel RF, Larrier N, Dodd L, et al. The clinical management of chondrosarcoma. Curr Treat Options Oncol. 2009;10:94-106.
Ciernik IF, Niemierko A, Harmon DC, et al. Proton-based radiotherapy for unresectable or incompletely resected osteosarcoma. Cancer. 2011;117:4522-4530.
Oertel S, Blattmann C, Rieken S, et al. Radiotherapy in the treatment of primary osteosarcoma-a single center experience. Tumori. 2010;96:582-588.
DeLaney TF, Liebsch NJ, Pedlow FX, et al. Phase II study of high-dose photon/proton radiotherapy in the management of spine sarcomas. Int J Radiat Oncol Biol Phys. 2009;74:732-739.
Ghosh KM, Lee LH, Beckingsale TB, et al. Indeterminate nodules in osteosarcoma: what's the follow-up? Br J Cancer. 2018;118:634-638.
Saifuddin A, Baig MS, Dalal P, et al. The diagnosis of pulmonary metastases on chest computed tomography in primary bone sarcoma and musculoskeletal soft tissue sarcoma. Br J Radiol. 2021:20210088.
Cipriano C, Brockman L, Romancik J, et al. The clinical significance of initial pulmonary micronodules in young sarcoma patients. J Pediatr Hematol Oncol. 2015;37:548-553.
Davison R, Hamati F, Kent P. What effect do pulmonary micronodules detected at presentation in patients with osteosarcoma have on 5-year overall survival? J Clin Med. 2021;10:1213.
Aryal A, Kumar VS, Shamim SA, et al. What is the comparative ability of 18f-fdg pet/ct, 99mtc-mdp skeletal scintigraphy, and whole-body MRI as a staging investigation to detect skeletal metastases in patients with osteosarcoma and Ewing sarcoma? Clin Orthop Relat Res. 2021.479(8):1768-1779.
Liu F, Zhang Q, Zhou D, et al. Effectiveness of (18)F-FDG PET/CT in the diagnosis and staging of osteosarcoma: a meta-analysis of 26 studies. BMC Cancer. 2019;19:323.
Palmerini E, Colangeli M, Nanni C, et al. The role of FDG PET/CT in patients treated with neoadjuvant chemotherapy for localized bone sarcomas. Eur J Nucl Med Mol Imaging. 2017;44:215-223.
Rothermundt C, Seddon BM, Dileo P, et al. Follow-up practices for high-grade extremity osteosarcoma. BMC Cancer. 2016;16:301.
Paioli A, Rocca M, Cevolani L, et al. Osteosarcoma follow-up: chest X-ray or computed tomography? Clin Sarcoma Res. 2017;7:3.
Puri A, Gulia A, Hawaldar R, et al. Does intensity of surveillance affect survival after surgery for sarcomas? Results of a randomized noninferiority trial. Clin Orthop Relat Res. 2014;472:1568-1575.
Puri A, Ranganathan P, Gulia A, et al. Does a less intensive surveillance protocol affect the survival of patients after treatment of a sarcoma of the limb? updated results of the randomized TOSS study. Bone Joint J. 2018;100-B:262-268.
Andrews CC, Siegel G, Smith S. rehabilitation to improve the function and quality of life of soft tissue and bony sarcoma patients. Patient Relat Outcome Meas. 2019;10:417-425.
Assi M, Ropars M, Rebillard A. The practice of physical activity in the setting of lower-extremities sarcomas: a first step toward clinical optimization. Front Physiol. 2017;8:833.
Wu WW, Yu TH, Jou ST, et al. Physical activity self-efficacy mediates the effect of symptom distress on exercise involvement among adolescents undergoing cancer treatment. Eur J Cancer Care (Engl). 2019;28:e13045.
Sheill G, Guinan EM, Peat N, et al. Considerations for exercise prescription in patients with bone metastases: a comprehensive narrative review. PM R. 2018;10:843-864.
Kosir U, Bowes L, Taylor RM, et al. Psychological adaptation and recovery in youth with sarcoma: a qualitative study with practical implications for clinical care and research. BMJ Open. 2020;10:e038799.
Campbell KM, Shulman DS, Grier HE, et al. Role of bone marrow biopsy for staging new patients with Ewing sarcoma: a systematic review. Pediatr Blood Cancer. 2021;68:e28807.
Newman EN, Jones RL, Hawkins DS. An evaluation of [F-18]-fluorodeoxy-D-glucose positron emission tomography, bone scan, and bone marrow aspiration/biopsy as staging investigations in Ewing sarcoma. Pediatr Blood Cancer. 2013;60:1113-1117.
Cesari M, Righi A, Colangeli M, et al. Bone marrow biopsy in the initial staging of Ewing sarcoma: experience from a single institution. Pediatr Blood Cancer. 2019;66:e27653.
Inagaki C, Shimoi T, Sumiyoshi Okuma H, et al. Bone marrow examination in patients with Ewing sarcoma/peripheral primitive neuroectodermal tumor without metastasis based on (18)F-fluorodeoxyglucose positron emission tomography/computed tomography. Med Oncol. 2019;36:58.
Kasalak O, Glaudemans A, Overbosch J, et al. Can FDG-PET/CT replace blind bone marrow biopsy of the posterior iliac crest in Ewing sarcoma? Skeletal Radiol. 2018;47:363-367.
Kalus S, Saifuddin A. Whole-body MRI vs bone scintigraphy in the staging of Ewing sarcoma of bone: a 12-year single-institution review. Eur Radiol. 2019;29:5700-5708.
Ingley KM, Wan S, Voo S, et al. Is it time to call time on bone marrow biopsy for staging Ewing sarcoma (ES)? Cancers (Basel). 2021;13:3261.
Oberlin O, Rey A, Desfachelles AS, et al. Impact of high-dose busulfan plus melphalan as consolidation in metastatic Ewing tumors: a study by the Societe Francaise des Cancers de l'Enfant. J Clin Oncol. 2006;24:3997-4002.
McTiernan A, Driver D, Michelagnoli MP, et al. High dose chemotherapy with bone marrow or peripheral stem cell rescue is an effective treatment option for patients with relapsed or progressive Ewing's sarcoma family of tumours. Ann Oncol. 2006;17:1301-1305.
Luksch R, Tienghi A, Hall KS, et al. Primary metastatic Ewing's family tumors: results of the Italian Sarcoma Group and Scandinavian Sarcoma Group ISG/SSG IV study including myeloablative chemotherapy and total-lung irradiation. Ann Oncol. 2012;23:2970-2976.
Ladenstein R, Potschger U, Le Deley MC, et al. Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial. J Clin Oncol. 2010;28:3284-3291.
Whelan J, Le Deley MC, Dirksen U, et al. High-dose chemotherapy and blood autologous stem-cell rescue compared with standard chemotherapy in localized high-risk ewing sarcoma: results of EURO-E.W.I.N.G.99 and Ewing-2008. J Clin Oncol. 2018:JCO2018782516.
Dirksen U, Brennan B, Le Deley MC, et al. High-Dose chemotherapy compared with standard chemotherapy and lung radiation in Ewing sarcoma with pulmonary metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and Ewing 2008. J Clin Oncol. 2019;37:3192-3202.
Dirksen U, Bhadri V, Brichard B, et al. Efficacy of add-on treosulfan and melphalan high-dose therapy in patients with high-risk metastatic Ewing sarcoma: report from the International Ewing 2008R3 trial. J Clin Oncol. 2020;38:11501-11501.
Meyers PA, Krailo MD, Ladanyi M, et al. High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing's sarcoma does not improve prognosis. J Clin Oncol. 2001;19:2812-2820.
Yang X, Zhang L, Yang X, et al. Oncologic outcomes of pre- versus post-operative radiation in resectable soft tissue sarcoma: a systematic review and meta-analysis. Radiat Oncol. 2020;15:158.
Bedetti B, Wiebe K, Ranft A, et al. Local control in Ewing sarcoma of the chest wall: Results of the EURO-EWING 99 trial. Ann Surg Oncol. 2015;22:2853-2859.
Vogin G, Helfre S, Glorion C, et al. Local control and sequelae in localised Ewing tumours of the spine: a French retrospective study. Eur J Cancer. 2013;49:1314-1323.
Bekelman JE, Schultheiss T, Berrington De Gonzalez A. Subsequent malignancies after photon versus proton radiation therapy. Int J Radiat Oncol Biol Phys. 2013;87:10-12.
Merchant TE. Clinical controversies: proton therapy for pediatric tumors. Semin Radiat Oncol. 2013;23:97-108.
Chung CS, Yock TI, Nelson K, et al. Incidence of second malignancies among patients treated with proton versus photon radiation. Int J Radiat Oncol Biol Phys. 2013;87:46-52.
Leroy R, Benahmed N, Hulstaert F, et al. Proton therapy in children: a systematic review of clinical effectiveness in 15 pediatric cancers. Int J Radiat Oncol Biol Phys. 2016;95:267-278.
Rombi B, DeLaney TF, MacDonald SM, et al. Proton radiotherapy for pediatric Ewing's sarcoma: initial clinical outcomes. Int J Radiat Oncol Biol Phys. 2012;82:1142-1148.
Sklar C. Maintenance of ovarian function and risk of premature menopause related to cancer treatment. J Natl Cancer Inst Monogr. 2005:25-27.
Critchley HO, Wallace WH. Impact of cancer treatment on uterine function. J Natl Cancer Inst Monogr. 2005:64-68.
Gross E, Champetier C, Pointreau Y, et al. Normal tissue tolerance to external beam radiation therapy: ovaries. Cancer Radiother. 2010;14:373-375.
Wallace WH, Thomson AB, Kelsey TW. The radiosensitivity of the human oocyte. Hum Reprod. 2003;18:117-121.
Haie-Meder C, Mlika-Cabanne N, Michel G, et al. Radiotherapy after ovarian transposition: ovarian function and fertility preservation. Int J Radiat Oncol Biol Phys. 1993;25:419-424.
Hoekman EJ, Broeders E, Louwe LA, et al. Ovarian function after ovarian transposition and additional pelvic radiotherapy: a systematic review. Eur J Surg Oncol. 2019;45:1328-1340.
Yamada Y, Lovelock DM, Yenice KM, et al. Multifractionated image-guided and stereotactic intensity-modulated radiotherapy of paraspinal tumors: a preliminary report. Int J Radiat Oncol Biol Phys. 2005;62:53-61.
Nevelsky A, Borzov E, Daniel S, et al. Perturbation effects of the carbon fiber-PEEK screws on radiotherapy dose distribution. J Appl Clin Med Phys. 2017;18:62-68.
Barnett JR, Gikas P, Gerrand C, et al. The sensitivity, specificity, and diagnostic accuracy of whole-bone MRI for identifying skip metastases in appendicular osteosarcoma and Ewing sarcoma. Skeletal Radiol. 2020;49:913-919.
Theruvath AJ, Siedek F, Muehe AM, et al. Therapy response assessment of pediatric tumors with whole-body diffusion-weighted MRI and FDG PET/MRI. Radiology. 2020;296:143-151.
Nicoli F, Saleh DB, Ragbir M, et al. Response to: comment on “Intraoperative near-infrared fluorescence (NIR) imaging with indocyanine green (ICG) can identify bone and soft tissue sarcomas which may provide guidance for oncological resection. Ann Surg. 2020. doi: 10.1097/SLA.0000000000004569.
Laitinen MK, Parry MC, Albergo JI, et al. Is computer navigation when used in the surgery of iliosacral pelvic bone tumours safer for the patient? Bone Joint J. 2017;99-B:261-266.
Tate R, Gerrand C, Hale J. Tibial turn-up procedure as an alternative to rotationplasty in a 4-year-old with osteosarcoma of the distal femur. J Pediatr Orthop B. 2015;24:50-55.
Hebert JS, Rehani M, Stiegelmar R. Osseointegration for lower-limb amputation: a systematic review of clinical outcomes. JBJS Rev. 2017;5: e10.
Jeys LM, Thorne CJ, Parry M, et al. A novel system for the surgical staging of primary high-grade osteosarcoma: the Birmingham classification. Clin Orthop Relat Res. 2017;475:842-850.
Fujiwara T, Medellin MR, Sambri A, et al. Preoperative surgical risk stratification in osteosarcoma based on the proximity to the major vessels. Bone Joint J. 2019;101-B:1024-1031.
Mumith A, Coathup M, Chimutengwende-Gordon M, et al. Augmenting the osseointegration of endoprostheses using laser-sintered porous collars: an in vivo study. Bone Joint J. 2017;99-B:276-282.
Parry MC, Laitinen MK, Albergo JI, et al. Silver-coated (Agluna(R)) tumour prostheses can be a protective factor against infection in high risk failure patients. Eur J Surg Oncol. 2019;45:704-710.
Davis LE, Bolejack V, Ryan CW, et al. Randomized double-blind phase ii study of regorafenib in patients with metastatic osteosarcoma. J Clin Oncol. 2019;37:1424-1431.
Duffaud F, Mir O, Boudou-Rouquette P, et al. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol. 2019;20:120-133.
Attia S, Bolejack V, Ganjoo KN, et al. A phase II trial of regorafenib (REGO) in patients (pts) with advanced Ewing sarcoma and related tumors (EWS) of soft tissue and bone: SARC024 trial results. Presented at the ASCO, May 20, 2017
Duffaud F, Blay J, Mir O, et al. LBA68: results of the randomized, placebo (PL)-controlled phase II study evaluating the efficacy and safety of regorafenib (REG) in patients (pts) with metastatic relapsed Ewing sarcoma (ES), on behalf of the French Sarcoma Group (FSG) and UNICANCER. Presented at the ESMO virtual conference, September 20, 2020
Italiano A, Mir O, Mathoulin-Pelissier S, et al. Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020;21:446-455.
Xie L, Xu J, Sun X, et al. Apatinib for advanced osteosarcoma after failure of standard multimodal therapy: an open label phase II clinical trial. Oncologist. 2019;24:e542-e550.
Gaspar N, Bautista Sirvent FJ, Venkatramani R, et al. Phase I combination dose-finding/phase II expansion cohorts of lenvatinib + etoposide + ifosfamide in patients (pts) aged 2 to ≤25 years with relapsed/refractory (r/r) osteosarcoma. Presented at the European Society for Medical Oncology (ESMO), 2019
Brenner JC, Feng FY, Han S, et al. PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma. Cancer Res. 2012;72:1608-1613.
Choy E, Butrynski JE, Harmon DC, et al. Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy. BMC Cancer. 2014;14:813.
Schafer ES, Rau RE, Berg SL, et al. Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411). Pediatr Blood Cancer. 2020;67:e28073.
Chugh R, Ballman KV, Helman LJ, et al. SARC025 arms 1 and 2: A phase 1 study of the poly(ADP-ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma. Cancer. 2021;127:1301-1310.
Smith MA, Reynolds CP, Kang MH, et al. Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program. Clin Cancer Res. 2015;21:819-832.
Engert F, Kovac M, Baumhoer D, et al. Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics. Oncotarget. 2017;8:48794-48806.
Holme H, Gulati A, Brough R, et al. Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of. BRCAness Sci Rep. 2018;8: 10614.
Jones DTW, Banito A, Grunewald TGP, et al. Molecular characteristics and therapeutic vulnerabilities across paediatric solid tumours. Nat Rev Cancer. 2019;19: 420-438.
Tawbi HA, Burgess M, Bolejack V, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017;18:1493-1501.
D'Angelo SP, Mahoney MR, Van Tine BA, et al. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol. 2018;19:416-426.
Paoluzzi L, Cacavio A, Ghesani M, et al. Response to anti-PD1 therapy with nivolumab in metastatic sarcomas. Clin Sarcoma Res. 2016;6:24.
Sundara YT, Kostine M, Cleven AH, et al. Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy. Cancer Immunol Immunother. 2017;66:119-128.
Dobrenkov K, Ostrovnaya I, Gu J, et al. Oncotargets GD2 and GD3 are highly expressed in sarcomas of children, adolescents, and young adults. Pediatr Blood Cancer. 2016;63:1780-1785.
Wingerter A, El Malki K, Sandhoff R, et al. Exploiting gangliosides for the therapy of Ewing's sarcoma and H3K27M-Mutant diffuse midline glioma. Cancers (Basel). 2021 Feb; 13(3):520.
Mody R, Yu AL, Naranjo A, et al. Irinotecan, temozolomide, and dinutuximab with gm-csf in children with refractory or relapsed neuroblastoma: a report from the children's oncology group. J Clin Oncol. 2020;38:2160-2169.
Erkizan HV, Kong Y, Merchant M, et al. A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase a inhibits growth of Ewing's sarcoma. Nat Med. 2009;15:750-756.
Zollner SK, Selvanathan SP, Graham GT, et al. Inhibition of the oncogenic fusion protein EWS-FLI1 causes G2-M cell cycle arrest and enhanced vincristine sensitivity in Ewing's sarcoma. Sci Signal. 2017;10:eaam8429.
Ludwig J, Federman, NC, Anderson PM, et al. TK216 for relapsed/refractory Ewing sarcoma: Interim phase 1/2 results. J Clin Oncol. 2021;39:11500-11500.
Fern LA, Lewandowski JA, Coxon KM, et al. Available, accessible, aware, appropriate, and acceptable: a strategy to improve participation of teenagers and young adults in cancer trials. Lancet Oncol. 2014;15:e341-350.
Avila JC, Livingston JA, Rodriguez AM, et al. Disparities in adolescent and young adult sarcoma survival: analyses of the Texas cancer registry and the National SEER Data. J Adolesc Young Adult Oncol. 2018;7:681-687.
Coccia PF. Overview of adolescent and young adult oncology. J Oncol Pract. 2019;15:235-237.
Wolfson JA, Richman JS, Sun CL, et al. Causes of inferior outcome in adolescents and young adults with acute lymphoblastic leukemia: across oncology services and regardless of clinical trial enrollment. Cancer Epidemiol Biomarkers Prev. 2018;27:1133-1141.
Saloustros E, Stark DP, Michailidou K, et al. The care of adolescents and young adults with cancer: results of the ESMO/SIOPE survey. ESMO Open. 2017;2:e000252.
Bleyer A, Barr R, Hayes-Lattin B, et al. The distinctive biology of cancer in adolescents and young adults. Nat Rev Cancer. 2008;8:288-298.
Herbert A, Lyratzopoulos G, Whelan J, et al. Diagnostic timeliness in adolescents and young adults with cancer: a cross-sectional analysis of the BRIGHTLIGHT cohort. Lancet Child Adolesc Health. 2018;2:180-190.
Magni C, Segre C, Finzi C, et al. Adolescents' health awareness and understanding of cancer and tumor prevention: when and why an adolescent decides to consult a physician. Pediatr Blood Cancer. 2016;63:1357-1361.
Reed DR, Naghavi A, Binitie O. Sarcoma as a model for adolescent and young adult care. J Oncol Pract. 2019;15:239-247.
Anderson P, Wells P, Lazarte T, et al. Outpatient chemotherapy, family-centered care, electronic information, and education in adolescenets and young adults with osteosarcoma. Clin Oncol Adolesc Young Adults. 2013;3:1-11.
Hendershot E, Volpe J, Taylor T, et al. Outpatient high-dose methotrexate for osteosarcoma: it's safe and feasible, if you want it. J Pediatr Hematol Oncol. 2019;41:394-398.
Elshahoubi A, Alnassan A, Sultan I. Safety and cost-effectiveness of outpatient administration of high-dose chemotherapy in children with Ewing sarcoma. J Pediatr Hematol Oncol. 2019;41:e152-e154.
Ferrari A, Stark D, Peccatori FA, et al. Adolescents and young adults (AYA) with cancer: a position paper from the AYA working group of the European Society for Medical Oncology (ESMO) and the European Society for Paediatric Oncology (SIOPE). ESMO Open. 2021;6:100096.
NICE. NIfHaCE-: Guidance on cancer services: improving outcomes in children and young people with cancer-the manual, August 2005
Oktay K, Harvey BE, Partridge AH, et al. fertility preservation in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2018;36:1994-2001.
Sorensen SD, Greve T, Wielenga VT, et al. Safety considerations for transplanting cryopreserved ovarian tissue to restore fertility in female patients who have recovered from Ewing's sarcoma. Future Oncol. 2014;10:277-283.
van der Kooi ALF, Kelsey TW, van den Heuvel-Eibrink MM, et al. Perinatal complications in female survivors of cancer: a systematic review and meta-analysis. Eur J Cancer. 2019;111:126-137.
Bleyer A, Tai E, Siegel S. Role of clinical trials in survival progress of American adolescents and young adults with cancer-and lack thereof. Pediatr Blood Cancer. 2018;65:e27074.
Ferrari A, Montello M, Budd T, et al. The challenges of clinical trials for adolescents and young adults with cancer. Pediatr Blood Cancer. 2008;50:1101-1104.
Gaspar N, Marshall LV, Binner D, et al. Joint adolescent-adult early phase clinical trials to improve access to new drugs for adolescents with cancer: proposals from the multi-stakeholder platform-ACCELERATE. Ann Oncol. 2018;29:766-771.
De R, Sutradhar R, Kurdyak P, et al. Incidence and predictors of mental health outcomes among survivors of adolescent and young adult cancer: a population-based study using the impact cohort. J Clin Oncol. 2021;39:1010-1019.
Fauske L, Bondevik H, Ahlberg K, et al. Identifying bone sarcoma survivors facing psychosocial challenges. a study of trajectories following treatment. Eur J Cancer Care (Engl). 2019;28:e13119.
Zeltzer LK, Recklitis C, Buchbinder D, et al. Psychological status in childhood cancer survivors: a report from the childhood cancer survivor study. J Clin Oncol. 2009;27:2396-2404.
Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence- SEER Research Data, 9 Registries, Nov 2019 Sub (1975-2017)- Linked to County Attributes- Time Dependent (1990- 2017) Income/Rurality, 1969- 2018 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2020, based on the November 2019 submission.
Joinpoint Regression Program, Version 4.6.0.0. April, 2018; Statistical Research and Applications Branch, National Cancer Institute. Statistical Research and Applications Branch, National Cancer Institute. Kim HJ, Fay MP, Feuer, EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 2000; 19:335-351 (correction: 2001;20:655).
Granowetter L, Womer R, Devidas M, et al. Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group study. J Clin Oncol. 2009;27:2536-2541.
Le Grange F. Advanced radiotherapy techniques: Improving outcomes in sarcoma., UCL (University College London), UCL Discovery, 2021
Gaspar N, Casanova M, Bautista Sirvent FJ, et al. Single-agent expansion cohort of lenvatinib (LEN) and combination dose-finding cohort of LEN + etoposide (ETP) + ifosfamide (IFM) in patients (pts) aged 2 to ≤25 years with relapsed/refractory osteosarcoma (OS). J Clin Oncol. 2018;36:11527-11527.
Federico SM, Pappo AS, Sahr N, et al. A phase I trial of talazoparib and irinotecan with and without temozolomide in children and young adults with recurrent or refractory solid malignancies. Eur J Cancer. 2020;137:204-213.